Accelerate Diagnostics Growth, Revenue, Number of Employees and Funding
Navigation
Overview
Estimated Revenue & Financials
- Accelerate Diagnostics's estimated revenue is currently $56.7M per year.
- Accelerate Diagnostics's estimated revenue per employee is $234405
Employee Data
- Accelerate Diagnostics has 242 Employees.
- Accelerate Diagnostics grew their employee count by -4% last year.
- Accelerate Diagnostics currently has 1 job openings.
What Is Accelerate Diagnostics?
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company's revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. In addition to the ID/AST development pipeline, the company also owns and licenses its proprietary OptiChem surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
keywords:N/A242
Number of Employees
$56.7M
Revenue (est)
1
Current Jobs
-4%
Employee Growth %
N/A
Total Funding
N/A
Valuation
N/A
Accelerator
N/A
Type
Similar Companies
Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
$8M | 34 | 17% | $2.5M | |
$56.7M | 242 | -4% | ||
$22.3M | 95 | 2% | ||
$8M | 34 | 6% | ||
$9M | 39 | 0% | ||
$66.3M | 282 | 16% | ||
$10.3M | 44 | 26% |
Accelerate Diagnostics News
TUCSON, Ariz., Aug. 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second ...
Accelerate Diagnostics (NASDAQ:AXDX) is finally approaching an inflection point in their unit sales of the Pheno system, and hospitals are ...
Accelerate Diagnostics, Inc. (NasdaqCM:AXDX) has an ERP5 rank of 17303. The ERP5 Rank is an investment tool that analysts use to ...